JP2025508656A - 抗ウイルスプロドラッグ、中期及び長期作用型製剤、並びに方法 - Google Patents

抗ウイルスプロドラッグ、中期及び長期作用型製剤、並びに方法 Download PDF

Info

Publication number
JP2025508656A
JP2025508656A JP2024543104A JP2024543104A JP2025508656A JP 2025508656 A JP2025508656 A JP 2025508656A JP 2024543104 A JP2024543104 A JP 2024543104A JP 2024543104 A JP2024543104 A JP 2024543104A JP 2025508656 A JP2025508656 A JP 2025508656A
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
compound
rvn
unsubstituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508656A5 (https=
Inventor
ワイ． ホステトラー，カール
ビードル，ジェームズ
ワリアエヴァ，ナデジャダ
ティー． スクーリー，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2025508656A publication Critical patent/JP2025508656A/ja
Publication of JP2025508656A5 publication Critical patent/JP2025508656A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024543104A 2022-01-26 2023-01-26 抗ウイルスプロドラッグ、中期及び長期作用型製剤、並びに方法 Pending JP2025508656A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303376P 2022-01-26 2022-01-26
US63/303,376 2022-01-26
PCT/US2023/011639 WO2023146974A2 (en) 2022-01-26 2023-01-26 Antiviral prodrugs, intermediate- and long-acting formulations and methods

Publications (2)

Publication Number Publication Date
JP2025508656A true JP2025508656A (ja) 2025-04-10
JP2025508656A5 JP2025508656A5 (https=) 2026-03-24

Family

ID=87472411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543104A Pending JP2025508656A (ja) 2022-01-26 2023-01-26 抗ウイルスプロドラッグ、中期及び長期作用型製剤、並びに方法

Country Status (7)

Country Link
US (1) US12594292B2 (https=)
EP (1) EP4469061A4 (https=)
JP (1) JP2025508656A (https=)
CN (1) CN118591377A (https=)
AU (1) AU2023213682B2 (https=)
CA (1) CA3247143A1 (https=)
WO (1) WO2023146974A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12173029B2 (en) 2020-07-24 2024-12-24 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
CA3247143A1 (en) 2022-01-26 2023-08-03 The Regents Of The University Of California Antiviral prodrugs, intermediate and long-acting formulations, and methods
CN117024479A (zh) * 2023-08-04 2023-11-10 杭州居维叶生物医药有限公司 一种聚乙二醇化磷酸前药及其制备与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167882A1 (en) * 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
WO2022046631A1 (en) * 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
WO2022265964A1 (en) * 2021-06-14 2022-12-22 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
JP2023535065A (ja) * 2020-07-24 2023-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ウイルスプロドラッグ、医薬製剤、及び方法
JP2023547599A (ja) * 2020-10-16 2023-11-13 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
DE60025172T2 (de) 1999-03-18 2006-09-21 Exiqon A/S Einstufige probezubereitung und bestimmung von nukleinsäure in biologischen proben
DE60029314T2 (de) 1999-03-24 2007-07-12 Exiqon A/S Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
US6734291B2 (en) 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
EP2558466A4 (en) * 2010-04-14 2013-11-13 Univ California PHOSPHONATES WITH REDUCED TOXICITY FOR THE TREATMENT OF VIRUS INFECTIONS
SG10201800188SA (en) 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
LT3043803T (lt) * 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
CN111808136B (zh) 2014-09-15 2024-06-11 加利福尼亚大学董事会 核苷酸类似物
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
US10874683B2 (en) 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CA3075950A1 (en) 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2021222535A1 (en) 2020-05-01 2021-11-04 Irazu Bio Method for treating respiratory viral infections comprising administration of fatty acid compositions
CA3247143A1 (en) 2022-01-26 2023-08-03 The Regents Of The University Of California Antiviral prodrugs, intermediate and long-acting formulations, and methods
WO2024159117A1 (en) 2023-01-26 2024-08-02 The Regents Of The University Of California Antiviral prodrugs, intermediate-and long-acting formulations, and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167882A1 (en) * 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
JP2023535065A (ja) * 2020-07-24 2023-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ウイルスプロドラッグ、医薬製剤、及び方法
WO2022046631A1 (en) * 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
JP2023547599A (ja) * 2020-10-16 2023-11-13 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
WO2022265964A1 (en) * 2021-06-14 2022-12-22 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHOOLEY,R.T. ET AL.: "Rethinking remdesivir: synthesis, antiviral activity, and pharmacokinetics of oral lipid prodrugs", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 65, no. 10, JPN6026012436, 2021, pages 01155 - 21, ISSN: 0005827084 *

Also Published As

Publication number Publication date
EP4469061A4 (en) 2025-10-08
AU2023213682A1 (en) 2024-07-25
WO2023146974A3 (en) 2024-06-20
CA3247143A1 (en) 2023-08-03
WO2023146974A2 (en) 2023-08-03
CN118591377A (zh) 2024-09-03
US20250177428A1 (en) 2025-06-05
EP4469061A2 (en) 2024-12-04
US12594292B2 (en) 2026-04-07
AU2023213682B2 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
JP7794798B2 (ja) 抗ウイルスプロドラッグ、医薬製剤、及び方法
AU2023213682B2 (en) Antiviral prodrugs, intermediate- and long-acting formulations and methods
CA2998189C (en) Methods for treating arenaviridae and coronaviridae virus infections
JP7559223B2 (ja) リン脂質化合物及びその使用
AU2021361059B2 (en) Phospholipid compounds and uses thereof
AU2014217892B2 (en) Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
AU2016304899A1 (en) Cyclic di-nucleotide compounds as sting agonists
KR20210152015A (ko) 필로비리다에 바이러스 감염을 치료하는 방법
WO2024159117A1 (en) Antiviral prodrugs, intermediate-and long-acting formulations, and methods
CN118922431A (zh) 5’-修饰的碳环核糖核苷酸衍生物及使用方法
Singh et al. Prodrug Strategies for the Development of β-l-5-((E)-2-Bromovinyl)-1-((2 S, 4 S)-2-(hydroxymethyl)-1, 3-(dioxolane-4-yl)) uracil (l-BHDU) against Varicella Zoster Virus (VZV)
HK40096311B (en) Phospholipid compounds and uses thereof
HK40096311A (en) Phospholipid compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260330